{"id":158576,"date":"2026-09-03T13:35:13","date_gmt":"2026-09-03T13:35:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/158576\/"},"modified":"2026-09-03T13:35:13","modified_gmt":"2026-09-03T13:35:13","slug":"wegovys-german-debut-opens-a-new-front-for-novo-nordisk-nvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/158576\/","title":{"rendered":"Wegovy\u2019s German Debut Opens a New Front for Novo Nordisk (NVO)"},"content":{"rendered":"\n

Novo Nordisk A\/S (NYSE:NVO<\/a>) has launched its Wegovy weight-loss pill in Germany, making it the first country in the European Union where the oral version of the drug is available. Germany is the EU’s largest pharmaceutical market, so the launch is an important step for Novo as it works to strengthen its position in the growing obesity-drug market. <\/p>\n

The pill contains semaglutide, the same active ingredient used in Novo’s Wegovy injection and Ozempic. Prices will vary depending on the dosage and are expected to be similar to the injectable version of Wegovy, which currently sells at pharmacy retail prices of around \u20ac170 to \u20ac280 in Germany. <\/p>\n

The launch comes as Novo faces growing competition from Eli Lilly. Novo Nordisk A\/S (NYSE:NVO) said in August that its Wegovy pill had captured around 90% of the oral obesity market, despite competition from Lilly. Lilly’s Foundayo has already launched in the UK and is expected to enter other major markets in 2027. <\/p>\n

\"Wegovy's<\/a> Wegovy\u2019s German Debut Opens a New Front for Novo Novo Gains an Early Edge in Europe’s Obesity Pill Market <\/p>\n

Launching the Wegovy pill in Germany gives Novo Nordisk A\/S (NYSE:NVO) another opportunity to strengthen its position in the rapidly growing obesity-drug market. Since Germany is the EU’s largest pharmaceutical market, being the first to launch an oral Wegovy there could give Novo an early advantage before competing products become more widely available. <\/p>\n

The pill also addresses one of the main challenges with injectable GLP-1 drugs: some patients are reluctant to use injections. Novo’s oral version uses the same semaglutide ingredient found in Wegovy and Ozempic, allowing the company to benefit from existing brand recognition and clinical experience. Novo estimates that pills could account for more than one-third of GLP-1 use by 2030, making the oral segment an important opportunity for future growth. <\/p>\n

Early market performance also gives investors some reason for optimism. Novo said during its second-quarter results that the Wegovy pill had captured around 90% of the oral obesity market despite competition from Eli Lilly. If Novo is able to achieve similar results in other European markets, the German launch could help the company regain momentum in its obesity business. <\/p>\n

Wegovy’s New Market Comes With Familiar Challenges <\/p>\n

The launch in Germany does not remove the competitive pressure Novo Nordisk is facing. Eli Lilly is already expanding its own oral obesity treatment, Foundayo, which launched in the UK in August and is under regulatory review in more than 40 markets. Lilly expects to expand the product internationally in 2027, which could reduce Novo’s early advantage. <\/p>\n

Novo Nordisk A\/S (NYSE:NVO) is also facing concerns about its overall growth outlook. Reuters reported that the company has come under pressure after losing ground to Lilly’s Zepbound, while recent results showed weaker-than-expected sales for the new Wegovy pill. Concerns about Novo’s pipeline have also increased following setbacks involving next-generation obesity treatments. <\/p>\n

Pricing could present another challenge. The Wegovy pill is expected to be priced broadly in line with the injectable version, with pharmacy prices of around \u20ac170 to \u20ac280 depending on the dosage. Since German patients currently have to pay for obesity treatments themselves, the cost could limit demand and reduce the size of the potential market. <\/p>\n

Conclusion <\/p>\n

The launch of the Wegovy pill in Germany is a positive development for Novo Nordisk A\/S (NYSE:NVO). It gives the company a more convenient oral version of Wegovy and an early position in Europe’s growing obesity-pill market. The product’s strong initial market share also suggests there is meaningful demand for the treatment. <\/p>\n

Still, the launch alone is unlikely to solve Novo’s broader growth challenges. Competition from Eli Lilly, pricing concerns, and uncertainty around Novo’s pipeline remain important risks. The longer-term success of the Wegovy pill will depend on whether Novo can maintain its early lead and turn growing demand for oral GLP-1 treatments into sustainable growth. <\/p>\n

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the <\/a>best short-term AI stock<\/a>. <\/p>\n

READ NEXT: Novartis (NVS)’s Cell Therapy Promise Meets a Safety Challenge<\/a> and Ares Management (ARES) Finds Opportunity in Student Housing as Demand Remains Resilient<\/a> <\/p>\n

Disclosure: None. This article is originally published at\u00a0Insider Monkey<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) has launched its Wegovy weight-loss pill in Germany, making it the first country in…\n","protected":false},"author":2,"featured_media":158577,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[190,20640,3845,272,1273,3859,278,1910,74259],"class_list":["post-158576","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-germany","tag-lilly","tag-novo","tag-novo-nordisk","tag-novo-nordisk-a-s","tag-nvo","tag-nyse","tag-wegovy","tag-wegovy-and-ozempic"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117207375939089669","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/158576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=158576"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/158576\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/158577"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=158576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=158576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=158576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}